Drug Profile
KN 042
Alternative Names: KN-042Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Type-2-diabetes-mellitus in China
- 11 Feb 2022 KN 042 is still in research development for Type 2 diabetes mellitus in China (unspecified route) (Alphamab pipeline, February 2022)
- 12 Jul 2019 KN 042 is still in early research for Type-2 diabetes mellitus in China (Alphamab pipeline, July 2019)